Piper Sandler analyst Edward Tenthoff raised the firm’s price target on Opko Health (OPK) to $6 from $4 and reiterates an Overweight rating on the shares. The stock in afternoon trading is up 5% to $4.04. The analyst says “continued strong” SARS-CoV-2 PCR and growing antibody testing at BioReference Labs increases his confidence in the company’s Service revenue forecast of $225M in Q2 and $896M this year. Further, partner Pfizer (PFE) will file in the Biologics License Application and Market Authorization Application for once-weekly somatrogon for treatment of growth hormone deficiency children this year, Tenthoff tells investors in a research note.